FONT-SIZE Plus   Neg

Pfizer's Phase 3 Study Of Torisel In Combination With Bevacizumab Fails

Pfizer Inc (PFE) Friday announced that its Phase 3 INTORACT trial , evaluating the combination of bevacizumab plus TORISEL compared with bevacizumab plus interferon-alfa-2a, or IFN-a-2a, did not meet its primary endpoint of superiority in extending progression free survival , or PFS, in the study population.

The company stated that the Phase 3 trial was carried out in the first-line treatment of patients with advanced renal cell carcinoma, or RCC, across risk groups.

The company further stated that the combination of bevacizumab and IFN-a-2a is approved as first-line treatment for advanced RCC and clinical supplies of both of these drugs in this trial were provided through an agreement with Roche.

"This trial advances our knowledge about the role and limitations of combining targeted therapies in the treatment of advanced RCC," said Dr. Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer's Oncology Business Unit. "Additional analyses will be performed to help us understand this result. The study outcome, involving combination therapy, does not change the safety and efficacy relationship of single-agent TORISEL for advanced RCC patients with a poor prognostic risk profile."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Xbox Live users are aggravated about repeated outages that have prevented gamers from accessing online multiplayer features. Blaming higher egg prices and other rising costs, Dunkin's Donuts will close 100 stores, all of them Speedway gas station and convenience store locations. Micron Technology, Inc. said that its fourth quarter profit fell 59% from last year, as sales declined and gross margins deteriorated amid weak demand and pricing pressures due to continued softness in the personal computer market. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly sales.
comments powered by Disqus
Trade PFE now with 
Follow RTT